"power lunch" oochlt -- amgen hitting 52-week highs. analysts say it's positive findings from another study that are trumping that failure. also according to a new filing, hedge fund third point taking a stake in the company. all of this pushing shares of amgen up about 3.5% today. tyler, back to you. >> thank you so much. >>> consumer reports just posted its review of amazon's first smartphone. so how does the fire stack up against the competition? the first on-air review from mike gekus. you didn't love it, mike. one of the problems you cited is, i guess, the way it is so closely tied to amazon's retail interests. >> that's right. it's more like trapped in amazon's retail world. it's not as though you need that phone to tap into all of the content and wonderful things that amazon has to offer. other phones -- my 2-year-old android phone can get most of the benefits that amazon offers. what happens with the fire is that it's locked out of google's play app store, which prevents people from downloading very popular google apps, things t

their oral drug has a better profile than this comund from amgen.e to inject it into the skin so we ultimately think it's going to get a much smaller sort of niche market at the end of the line. >> as i recall, thalidomide was like anti-angiogenesis. do they all work that way? i don't even know why that would work with multiple myeloma but are they different modes of action? or do they do the same thing? >> yeah, they're a little different you're right. thalidomide was an anti-angiogenic drug but we found it actually change the way the bone marrow works and how the cancer is able to grow or not grow in that environment. this drug is different. it's a different mechanism of action. this is going to compete agai t against -- so it's not quite the same. >> okay. all right. doesn't look like the drug is dead that's for sure. only down a couple of points. anyway, y aftaron. thanks. i appreciate it. >> right. any time, thank you. >>> the american consumer is in focus today. walmart's earnings matching estimates. more retailers are going to be hitting the

amgen, big winner. let's go to the new york stock exchange. nicole?the fight against breast cancer, a recent treatment from amgen. the stock is up about 1%. blood cancer treatment for patients without the disease worsening. the people who use this drug in collaboration with other drugs live with a median of 26 months without the condition worsening, versus 17 months. it shows promise it. may move it from accelerated approval to full approval, that could be great. it is the world's largest biotech company, this is great news for amgen and those fighting blood cancer. charles: thank you very much. some more news regarding the ebola outbreak, authorities ordering all ebola victims to be cremated as the virus shows no sign of slowing down. the mandate to cremate victims, people are fear of contamination. next update on ebola, american victim dr. kent brantly arrived in atlanta. you can see photos of him getting out on his own to receive treatment of the deadly disease. this is the first time a patient with ebola was allowed to return back to this country,

shares up to $155.60 and shares of amgen hit a record despite a bach of mixed news. the bio tech company released ki disappointing treatments and recalled a drug from the middle east but positive findings from another study are trumping the failure and according to a new file, that helped push shares up 3.5% to $131.86. >>> meanwhile, mirk got the okay for a new type of sleeping pill. the drug is designed to help people with insomnia to stay asleep. >>> so if you're a k-cup lover get ready to pay more. green mountain is raising prices by 9% for the portion packs of coffee. it blamed the price hike on expensive coffee bean prices and rising cost for energy, packaging and transportation. shares rose slightly. >>> coke and monster beverage are teaming up. coke took a 17% stake in monster worth more than $2 billion. the beverage giant will transfer the energy drink as part of the deal and monster will give coke the non-energy beverages. shares shot up by as much as 26% in after hours trading. during the regular session, the stock rose slightly to $71.65. >>> and it turns

its projects will include supplying gas turbines and rail -- amgen saw its shares rise after its company's blood cancer drug met its role in a late stage trial. the second most common form of blood cancer, multiple myeloma. two companies working hard on experimental ebola treatments. tetmira opened strongly in the hopes that its trial for the illness will be helpful in remedying the disease. shares of tech mira fell 7%. biochris saw its shares rise. it's worth mentioning that both of these are small cap stocks. >>> tenet health care posted a narrower than expected loss late today. the hospital operator raised its full outlook. shares were volatile in after hours trading. the stock was nearly 2% higher at 53.30. >>> p. f.chang's asian bistro is the last to admit card numbers may have been stolen. they got the cardholders name and card expiration date as well as the number. >>> sales in china are getting hit by last month's food safety scare which forced it to halt sales of certain items. in a regulatory filing, the world's largest burger chain said the affected markets account for 10% of it

. >> the next chart is amgen.his is where i'm looking at prior declines that were 19.92, 19.55, 20.76. you can see the last swings were very similar. not only similar in price but very similar in time. actually, they were equal in time. six weeks down and six weeks down. $20.80. you can't make that stuff up. >> remarkable. >> if we do continue to hold above there we are looking at a target of 136.61. >> that would be bullish. here is a loser. maybe not. >> not yet. this is an example. then i'm going to go into real time. in exxon we had symmetry of a prior decline that was $10.81. the next decline was $10.70. very similar but then we also had the retracement that came into that zone and an extension of low to high swing. we have the zone between 84 had the 14 to 84.68. we held it and you had a $16 rally off of it. that is in the past. >> that is in the past. now i think oil is headed down. i worry about this one. where could it be a down side target if things go bad? >> typically on a chart like this i would take

amgen is up more than 3% today, after investors shall rugged off disappointing results for the blood cancer treatment. also getting a fights. gillia, regen ron, vertex and bioagain, in fact the only big both tech that's not trading. taz about flag. analysts tell me biotechs are on the move because of an overall good earnings season. >>> we have about 50 minutes to go before the bell rings. the dow holding on to a pretty decent gain. that's a third of a percent. >>> now, going back to an issue we were just discussing, the u.s. versus europe. which is the better place for investors right now? dom chu and seema mody will go head to head in a classic "closing bell" debate. >>> also walmart slashing guidance because of sliding store in the united states. what they need to do to win shopper back. >> the state of the consumer, when, instant analysis and reaction to those numbers coming up. keep it right here. having the cloud allows us to rapid prototype a lot of ideas. being able to pay as we go was crucial for a start up. having to fork out a lot of money up front was risky. you can launc

don't bet against amgen. they paid a fortune for onyx and i think it's starting to pay off. who knows why cardinal health is down and it makes me inefficient. >> well, one reason we can point to, walt disney is one of the best performers. did you see guardians of galaxy this weekend? >> i know someone who did. they say, wait a second, why don't we see what they report. don't forget, one of the biggest buybacks has done a pretty good job. it's held up better than almost any other stock in the dow. >> and let's get to the buyback for one second. this is always a hot topic when we're talking about the increase in earnings, people say, yeah, but there's been a lot of buybacks. true. apple, for example, has seen net earnings grow 12%, earnings per share, 17 or 18. the point being that buybacks are down from q1 to the tune of 30%. so again, the fundamentals in this -- and this is the irony of the backdrop right now. earnings are pretty good. the economy story pretty good. geopolitical story, terrible. >> right. they can say, i did this, did i that. rates have flat lined. it's russ

we're seeing celgene, amgen hitting all-time highs yesterday.tell me that's because the second quarter was really good. these are all driven both by earnings but also about excitement about their pipelines. cellgene has got a big drug that's a blood cancer drug. it's tapped into the smaller biotechs through business development and partnerships. a lot of folks are really excited about that. amgen just did a restructuring, cut a lot of jobs. folks are excited about their emerging pipeline. they have a drug that targets cholesterol. gilead of course has that huge hepatitis-c drug. estimated to bring in $12 billion to $13 billion in its first year on the market. a lot of folks excited about that. they'll be bringing in a lot of cash. expected to do a lot of acquisitions. and rejeneron. they have long-term growth in a cholesterol drug sets up a space race over cholesterol between amgen, and you mentioned yellen's comments earlier. analysts are staying some of those fears might be waning a little bit. there was also some concern -- >> there were fear

you called out yellen on the biotech call, and amgen in the family.his trial did not go the way they hoped, one of the big losers this morning. >> yeah. they are getting good and bad, but i think that she, that the fed in particular, was talking about the intercepts and charles river labs on "mad money" the other day, and that's the place where you do the original, look, all the -- it was funny, listen, the guys who do the real science are companies that are small bioteches, and she described them as being stretched, but here's something -- they ain't stretched. no -- i think it's one that has one, that could be big. >> risk-reward on names may well be worth it. when they hit something, they are ten baggers. congratulations on that announcement. >> people like to hear about that. >> it happens. if you have a portfolio of them, yeah, may not hit, but one or two. >> look at regeneron. some say it's a household name, i hope it is, but zel gene, they say it's trying to cure arthritis. it's a diz if you cure or maintain art ri tis, i think that's the bigge

amgen, it hit 52-week highs today, i still see upside there. i see biogens as well. >> this was a stock trading basically $500 in march, had a huge pullback to 220 or. so when she talks about 100% upside. that's not that crazy. i know it seems nuts, look at the stock, extraordinarily volatile. about a 10% short interest. interesting name in a space. this isn't that crazy. it is a binary play. i think you are probably 75-25 it works. >> as you mentioned it went up to $500 bucks. >> 447, yes. >> when you say for the average investor, what is the risk? if one of these things fails or one outsources or outsizes its competition then the rest gets slammed. >> are you still hurting. >> did you feel the pain? >> yes. >> did you see me wince? so for me, put the stock, it's up right now. >> so grasso bought clovis. it was a bad trade. you are burned. >> hi, my name is steve grass so. i bought clovis. >> i am still long clovis. it's 31% off the bottom. if you are a home gamer, you buy the ibb. or you put parameters in or trade with pete. >> the posterboy

amgen had a spink quarter. as did gilead and celgene has been under fire. i think the race is in play. i don't think it's in a bubble. i don't think valuations are in that stretch. this is a headline. i get it. the more reasons to own these names. >> i'm hard pressed about anthrax or whatever it was, with rebuying the next day on fear was the right thing to do. >> right. >> so i definitely would stay away. >> biocryst, few look at the charts, it's not as if it was priced in, this event into a new valuation threshold, so in other words, around 12 to $13 bucks. this is where the stock has been trading the last year. not on ebola news, if you look at the valuation, they're not making money. it's a momentum stock you are basically playing with a lottery tick. it hasn't priced in this event if that's what you are looking for. >> coming up, the high cost of low prices, what wal-mart is doing to up the ante against amazon and why it may shake up the space later. getting ready to take a roadtrip over the summer. the turmoil and pain at the pump ahead. we are ba in

first of all, shares of amgen are down about a couple percent in the after-hours session.ntal drug for blood cancer, and they said that one of these did not meet its primary goal in the late-stage clinical trial. the company says that while unfortunate, they believe results from other late-stage trials of this drug could be sufficient enough for regulatory submissions around the world. maybe that's the reason why the losses, at least for now, are not quite as large as some might have expected. also, we're watching noodles. revenue of $100 million versus estimates of $103 million, so just a bit shy. earnings per shy came in short at 12 cents a share, excluding certain items, adjusted, if you will, versus estimates of 14 cents. it the company sees flat growth for the year. shares are down 17% in the after market. meanwhile, 3d printing, exone sinking following earnings, reporting a second-quarter loss of 32 cents a share versus estimates of a 14-cent-per-share loss. revenues also missed estimates, and as a result, bouncing off its lows, but still down, kelly, 8% on the day.

amgen and dr. pepper snapple. amazon, third season of pilots launched today. julia boorstin joins us with a look at the rollout. how they fit with amazon's strategy. >> hey, scott. amazon's original pilots free for anyone to watch and give feedback which the company should turn into series. they're packed with big names. oscar winner steven soderbergh and producer mark forrester and whit stalemaillman, making a de. and five more kids dvd projects. in july, spend $100 million on original video content this quarter. big increase over the quarter earlier and $20 million more than netflix this year. also luring more subscribers to unlimited shipping. shoppers spend significantly more on amazon. scott? >> okay. julia, thanks. is this amazon, guys, finally going to compete with netflix from a content standpoint? >> they already have a ton of songs on there, judge. they're getting more and more of their, this, what julia addressed, regional content. >> this is what matters. >> i don't want to dismiss the free streaming songs and all the rest. go free pandora, you're

perrigo is up and amgen is up 3.3%. >> that does it for this edition of "power lunch." >> "street signs" begins now. >>> welcome to "street signs," everybody. stocks are higher today but it does not mean that some investors aren't reaching for the pepto. why? first of all, there's the eurozone where growth is flattening. is it time to euro-proof your portfolio? we'll dig in on that ahead. >>> plus, back here in the united states, we have a piece of housing data that could make investors a little queasy. and wall street's top food analyst has a big stomachache on a recommendation that's gotten off. >>> also, a man that is no stranger to indigestion, mr. herb greenberg is having a very hard time digesting some of the recent food ipos. he joins us ahead. brian sullivan is on assignment out there. but we have a big surprise coming up for you. we have a very special guest who's going to be taking the ice bucket challenge live on "street signs." personally, i cannot wait. >>> but before we get to that action, let's get to what stocks are doing, touching their highest levels of august. the s&p

biotech also contributing to the outperformance with celgene, gilead and amgen at levels not seen. this hold? >> absolutely. >>> do my eyes deceive me? simon hobbs with the countdown to the close across europe. looking rather dry and warm. >> indeed. most of europe higher with the exception of germany. obviously a deescalation with the perception that the tensions with ukraine are not as bad as they were certainly on friday. so overall europe's up more than 1%. those that are exposed more to russia and to the crisis like germany have done even better as you can see a gain of almost 2% on where we are with the dax. the underlying state of the economy in europe, certainly the eurozone still in question. today the german central bank called into question whether it was right to assume that there would be a rebound in growth in the second half of the year. you know we had those terrible second quarter gdp numbers on thursday. because specifically, they say, of geopolitical risks. so that from the bank of germany. the bank of england also gave an interview over the weekend in which he s

names i like, abbott labs, amgen. mckesson. pki.arly health care gives you a little bit of the insulation against a lot of these global geopolitical events we're experiencing. it's a place i think you've got to be looking now. >> doc? >> plug power is one for me, judge. the stock's up 45% in the last month. of course, they supply power for the likes of fork lifts and that sort of thing. on-site poub power, but up nearly 300% year to date. from 230 million to a billion dollars, or thereabouts over the course of this year. >> momentum stock. >> a big momentum play here, and i've been in and out of this name this year. happy to be in it now. >> pete? >> i think a lot of people just continue to see some of these names but they don't come up. not exciting. hewlett-packard. the run, very exciting. it continues. meg whitman, talk two areas. microsoft, new management there. obviously, meg stepped in a couple years ago. look at the transition she's been able to make so far. two names. laser focused and areas of growth, so is hewlett-packard,

. >> shares of amgen are rising.a clinical trial or a late stage treatment for mold for myeloma was successful. a highare closing in on that was set last wednesday. microsoft is suing samsung electronics, alleging that they use the nuclear phone business as an excuse to stop complying with the contract then they signed in 2011. africa, betting on investing $2 billion in the continent by 2015. they say africa is at most promising growth region and made $5 billion in revenue from its operations there last year. aboutfrey immelt talking if shutting down the import export bank, that would be a big blow to their trading. autonation.ree is they posted july sale numbers that were the best since july 2006. it was an eight percent in greece -- increase from a year ago. sales of luxury premium vehicle surged 17% last month. >> michael kors first quarter sales rose last month. however, shares are down. the company has been taking market share, but the question is what will it cost them to continue this way? the ceo talking abou

. ♪ ♪ stuart: amgen stock is higher. of nearly 24% there. they have to pay them for what they say.is an interesting story. what is going on? >> the city violated state law. they said they were denied meal breaks. lumped in there was the napping on lunch breaks. they were not allowed to nap. that got lumped in with all of this. what happened was, they won. they got $26 million. 15,000 for these 1100 workers. they initially wanted 40 million. guess who gets a lot of money out of this? lawyers. stuart: so, you cannot say to your workforce no napping on your break. >> during business hours. stuart: you have to pay them $24 million. >> about $15,000. >> i am sorry. it is state and city workers in california. stuart: let's not forget. okay. got to move on. atlantic city struggling with rabble hotel and casino. it is announcing it will close its doors next month if it cannot find a buyer. we have the ceo of the authority. stuart: >> there is no dow about it. you are not able to go gambling. they have online gambling. it is home to atlantic city. they would take the problem gambler. i hate

all-time highs for apple, home depot, amgen, and dr. pepper-snaple. seen in the past with the big launch going higher. the team pointed out it peaked last time around in september just on the day before. >> absolutely. >> and dan on this program told us generally it under performs following the product launch. he thinks it will be different this time, but we have to wait pb. >> because a bigger range? >> thinks the pipeline is better, and judging where the stock was and is now, it's not that much more expensive relative to the market. >> best bargain, what did carl call apple? no brainer. >> the no brainer. >> of course, it's confirmed september 9 th, the date of the next product unveil. the leak of the apple, preparing to roll out touch pay technology, basically allowing your phone to work as your credit card as samsung and lg have curtesy of a dutch chip maker, who's stock we should check actually. >> i didn't realize the technology has been in phones the last eight to nine years, but it's not caught on. you whether apple -- >> talk about payments a

. >> unbelievable the list, gilead, celgene, regeneron, amgen, biogen, top ten. >> new valuations onunsung hero of the period, the regeneron ceo, when "mad money" started we couldn't get ceos to come on. heed hey $5 stuock, he had a formulation. this amazing drug, for macular degeneration, a winner. they've got other things in the fire. you start getting a company, you say, wow, that's multiple billion of dollars but you think, wait a second. if intermune is a bolt on for $8 billion, is what sanofi if they want to buy regeneron? regeneron, i like alone, it's doing so well. celgene, no one's going to buy celgene, it's too big. gilead, it's too big. look out, merck. look out, pfizer. they're coming to get you. >> we'll get stop trading with jim. s&p 1998.5 now. "squawk on the street" will be right back. we do? i took the trash out. i know. and thank you so much for that. i think we should get a medicare supplement insurance plan. right now? [ male announcer ] whether you're new to medicare or not, you may know it only covers about 80% of your part b medical expenses. it's up to you to

i like amgen, j&j as a health care mutual fund. i think those areas have had a great run. i'm concerned about the topness of the market. those guys have had a great one, facebooks, they will be a source of funds if we see volatility pick up. that's why i like companies with reasonable valuations and strong dividend growth, regardless of the sector. >> you don't like amazon, then, matt? >> hell no. excuse me, no way. you have a look at the company that's 853 times training -- >> wait a minute, hell yes. for the record. >> it's way cool, but way expensive there. >> for the record, granted, i do agree with matt, it is expensive. it's not profitable, but amazon's goal is not to reach profitability in the short term. they want to own everything and anybody. so, i think once they do that, they're going to be focused on profitability. but you know, they want to be the internet of everything. they want to have, you know, drones deliveries to your doorstep. so -- >> and twitch. >> i'm pretty bullish on amazon. >> thanks, guys. spirited debate about the nasdaq's next leg. my shanks

it holds shares in dupont, pfizer, amgen. something unlike many people have ever seen. >> well, they did have a little -- a big issue with the documentary that happened. blackstone, you weren't shocked? >> no, not really. >> it's one thing for a company to come out and say this has had no effect on it. in fact, it has actually increased attendance and then to completely do a 180 at the next quarter. >> how about people on twitser, joe? >> i think that's a little bit different. >> i don't know. when you're a private company, you can. you can choose who gets your shares and you can choose who your employees sell their shares to. but anyone can buy the shares. so we will see how that battle turns out. meanwhile, the nfl has a new idea to generate revenue. "the wall street journal" reports the league is asking artists who want to play next year's halftime show to pay to play. rihanna, katy perry and cold play are being looked at. but the pay to pay reception is not going over well, as you can imagine. normally you get paid to pla

amgen also gaining ground on news its blood cancer drug met its main goal in the late-stage trial, sharesnearly 3%. and let's end with michael kors, falling after the company said it expects margins to shrink for the year as it invests more to open stores across europe. kors down about 6.5%, kelly and bill, on today's trade. back over to you. >> thanks, dom. welcome back. >> yeah. good to see dom again. is this an opportunity for investors to get in on kors or is the company head ed the way of coach? >> dorothy lakna from topeka said it reiterates her buy rating while carl nirth thinks this stock is in the throes of bullish to bearish reversal. dorothy, michael kors was supposed to be the company that was taking all that market share away from coach. i mean, they were doing so well. what happened? what's going on here? >> well, i think they ton do so. they reported a much better-than-expected quarter. we were at 83 cents, they did 91. they beat by more than they did in the last quarter and saw very good comp growth across the regions, across the channels of distribution. they raised guida

watching shares of biotech giant amgen.ews this morning saying a new cancer drug improved survival rates in a late-stage trial. so, all good. all good. we are going to you, sir. >> yeah, i believe we're going to go to break. but the only way i'm going to make -- the only way i'm going to toss to break on this show is if you stop playing the frozen music. let's think about that. i want to get your comments on earnings -- ♪ ♪ let it go >> let it go, man. >> let it go. >> stocks -- i'm just going to get louder. stocks are supposed to be a future measure of earnings. now everything, geopolitical, the fed, everything's mixed and muddled. what an equity at its core is supposed to be. we forget that, right? hopefully one day it will go back to that. if it were to, is the stock market fairly valued in your mind given what you've seen from earnings? >> personally i think it's on the high end of reasonable at this point. >> high end of reasonable? >> meaning risks are poised to the downside. there's still room for improvement, becaus